» Articles » PMID: 24125746

Virus-like Particle-based Human Vaccines: Quality Assessment Based on Structural and Functional Properties

Overview
Specialty Biochemistry
Date 2013 Oct 16
PMID 24125746
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Human vaccines against three viruses use recombinant virus-like particles (VLPs) as the antigen: hepatitis B virus, human papillomavirus, and hepatitis E virus. VLPs are excellent prophylactic vaccine antigens because they are self-assembling bionanoparticles (20 to 60 nm in diameter) that expose multiple epitopes on their surface and faithfully mimic the native virions. Here we summarize the long journey of these vaccines from bench to patients. The physical properties and structural features of each recombinant VLP vaccine are described. With the recent licensure of Hecolin against hepatitis E virus adding a third disease indication to prophylactic VLP-based vaccines, we review how the crucial quality attributes of VLP-based human vaccines against all three disease indications were assessed, controlled, and improved during bioprocessing through an array of structural and functional analyses.

Citing Articles

DNA vaccines as promising immuno-therapeutics against cancer: a new insight.

Shariati A, Khezrpour A, Shariati F, Afkhami H, Yarahmadi A, Alavimanesh S Front Immunol. 2025; 15:1498431.

PMID: 39872522 PMC: 11769820. DOI: 10.3389/fimmu.2024.1498431.


Advancements in nanoparticle-based vaccine development against Japanese encephalitis virus: a systematic review.

Adugna T, Niu Q, Guan G, Du J, Yang J, Tian Z Front Immunol. 2025; 15:1505612.

PMID: 39759527 PMC: 11695416. DOI: 10.3389/fimmu.2024.1505612.


Optimizing the production of recombinant human papilloma virus type 52 major capsid protein L1 in Hansenula polymorpha.

Phimsen W, Kopitak N, Boontawon T, Theeranan T, Boonchird C, Pongtharangkul T Sci Rep. 2024; 14(1):28555.

PMID: 39558031 PMC: 11574089. DOI: 10.1038/s41598-024-79764-7.


A Single-Component Multilayered Self-Assembling Protein Nanoparticle Vaccine Based on Extracellular Domains of Matrix Protein 2 against Both Influenza A and B.

Zhang Y, Gomes K, Lee Y, Ward G, Xie B, Auclair S Vaccines (Basel). 2024; 12(9).

PMID: 39340007 PMC: 11435909. DOI: 10.3390/vaccines12090975.


Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.

Henriquez R, Munoz-Barroso I Heliyon. 2024; 10(15):e34927.

PMID: 39144987 PMC: 11320483. DOI: 10.1016/j.heliyon.2024.e34927.